{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T09:34:41Z","timestamp":1790415281429,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"am","delay-in-days":390,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.bulcan.2019.10.005","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T23:09:14Z","timestamp":1577142554000},"page":"262-271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Les dysthyro\u00efdies sous immunoth\u00e9rapie anti-canc\u00e9reuse"],"prefix":"10.1016","volume":"107","author":[{"given":"Christine","family":"Cugnet Anceau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Abeillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Maillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Borson-Chazot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Disse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bulcan.2019.10.005_bib0195","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/ijc.32132","article-title":"A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors","volume":"145","author":"Arnaud-Coffin","year":"2019","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2019.10.005_bib0200","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jc.2012-4075","article-title":"Endocrine side effects induced by immune checkpoint inhibitors","volume":"98","author":"Corsello","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.bulcan.2019.10.005_bib0205","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"10.1016\/j.bulcan.2019.10.005_bib0210","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2019.10.005_bib0215","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","author":"de Filette","year":"2019","journal-title":"Horm Metab Res"},{"issue":"5","key":"10.1016\/j.bulcan.2019.10.005_bib0220","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3\u00a0trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2019.10.005_bib0225","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/cen.13297","article-title":"Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4\u00a0and programmed death receptor protein-1\u00a0inhibitors in the treatment of melanoma","volume":"86","author":"Morganstein","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"10.1016\/j.bulcan.2019.10.005_bib0230","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1210\/jc.2017-00448","article-title":"Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms","volume":"102","author":"Delivanis","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.bulcan.2019.10.005_bib0235","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2019.10.005_bib0240","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1210\/jc.2014-4560","article-title":"Induction of painless thyroiditis in patients receiving programmed death 1\u00a0receptor immunotherapy for metastatic malignancies","volume":"100","author":"Orlov","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.bulcan.2019.10.005_bib0245","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1111\/cas.13800","article-title":"Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab","volume":"109","author":"Kimbara","year":"2018","journal-title":"Cancer Sci"},{"issue":"10","key":"10.1016\/j.bulcan.2019.10.005_bib0250","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1634\/theoncologist.2017-0375","article-title":"Incidence of thyroid function test abnormalities in patients receiving immune-checkpoint inhibitors for cancer treatment","volume":"23","author":"Patel","year":"2018","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.bulcan.2019.10.005_bib0255","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2019.10.005_bib0260","first-page":"1035","article-title":"Predictive factors of nivolumab-induced hypothyroidism in patients with non-small cell lung cancer","volume":"31","author":"Maekura","year":"2017","journal-title":"In Vivo"},{"issue":"3","key":"10.1016\/j.bulcan.2019.10.005_bib0265","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1210\/js.2017-00432","article-title":"Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study","volume":"2","author":"Kobayashi","year":"2018","journal-title":"J Endocr Soc"},{"issue":"6","key":"10.1016\/j.bulcan.2019.10.005_bib0270","first-page":"1225","article-title":"Potential risk factors for nivolumab-induced thyroid dysfunction","volume":"31","author":"Yamazaki","year":"2017","journal-title":"In Vivo"},{"issue":"15","key":"10.1016\/j.bulcan.2019.10.005_bib0275","doi-asserted-by":"crossref","first-page":"6585","DOI":"10.1002\/cam4.2533","article-title":"Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma","volume":"8","author":"Kassi","year":"2019","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.bulcan.2019.10.005_bib0280","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cen.13063","article-title":"Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review","volume":"85","author":"Joshi","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"10.1016\/j.bulcan.2019.10.005_bib0285","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1210\/jc.2016-2300","article-title":"Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab","volume":"101","author":"de Filette","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.bulcan.2019.10.005_bib0290","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/cncr.31200","article-title":"Endocrine dysfunction induced by immune checkpoint inhibitors: practical recommendations for diagnosis and clinical management","volume":"124","author":"Barroso-Sousa","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2019.10.005_bib0295","first-page":"2087525","article-title":"Treatment of Ipilimumab induced Graves\u2019 disease in a Patient with metastatic melanoma","volume":"2016","author":"Azmat","year":"2016","journal-title":"Case Rep Endocrinol"},{"key":"10.1016\/j.bulcan.2019.10.005_bib0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40842-018-0073-4","article-title":"Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports","volume":"5","author":"Tan","year":"2019","journal-title":"Clin Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.bulcan.2019.10.005_bib0305","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1530\/EJE-10-0833","article-title":"Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy","volume":"164","author":"Min","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.bulcan.2019.10.005_bib0310","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3109\/01676830.2014.949792","article-title":"Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab","volume":"33","author":"McElnea","year":"2014","journal-title":"Orbit"},{"issue":"1","key":"10.1016\/j.bulcan.2019.10.005_bib0315","first-page":"43","article-title":"Thyroid autoimmunity","volume":"197","author":"Orgiazzi","year":"2013","journal-title":"Bull Acad Natl Med"},{"issue":"1","key":"10.1016\/j.bulcan.2019.10.005_bib0320","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.gendis.2017.11.002","article-title":"Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma","volume":"5","author":"Angell","year":"2018","journal-title":"Genes Dis"},{"issue":"10","key":"10.1016\/j.bulcan.2019.10.005_bib0325","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1089\/thy.2017.0062","article-title":"Anti-PD-1\u00a0antibody therapy induces Hashimoto's disease with an increase in peripheral blood follicular helper T cells","volume":"27","author":"Torimoto","year":"2017","journal-title":"Thyroid"},{"issue":"6939","key":"10.1016\/j.bulcan.2019.10.005_bib0330","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature01621","article-title":"Association of the T-cell regulatory gene CTLA4\u00a0with susceptibility to autoimmune disease","volume":"423","author":"Ueda","year":"2003","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.bulcan.2019.10.005_bib0335","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.1210\/jc.2002-020492","article-title":"The genetics of autoimmune thyroid disease","volume":"87","author":"Vaidya","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bulcan.2019.10.005_bib0340","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3389\/fonc.2017.00056","article-title":"Incidence of immune-related adverse events with program death receptor-1- and program death receptor-1\u00a0ligand-directed therapies in genitourinary cancers","volume":"7","author":"Maughan","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.bulcan.2019.10.005_bib0345","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1\u00a0antibody therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"suppl 4","key":"10.1016\/j.bulcan.2019.10.005_bib0350","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2019.10.005_bib0355","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2019.10.005_bib0360","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/ERC-18-0320","article-title":"French Endocrine Society Guidance on endocrine side-effects of immunotherapy","volume":"26","author":"Castinetti","year":"2018","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2019.10.005_bib0365","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.bulcan.2019.02.003","article-title":"Immunotherapy-induced endocrinopathies: Insights from the 2018\u00a0French Endocrine Society Guidelines","volume":"106","author":"Castinetti","year":"2019","journal-title":"Bull Cancer"},{"issue":"7","key":"10.1016\/j.bulcan.2019.10.005_bib0370","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1089\/thy.2016.0562","article-title":"Clinical features of nivolumab-induced thyroiditis: a case series study","volume":"27","author":"Yamauchi","year":"2017","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.bulcan.2019.10.005_bib0375","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"issue":"12","key":"10.1016\/j.bulcan.2019.10.005_bib0190","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1158\/2326-6066.CIR-17-0208","article-title":"Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy","volume":"5","author":"Lee","year":"2017","journal-title":"Cancer Immunol Res"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455119304084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455119304084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:32:20Z","timestamp":1757791940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455119304084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0007455119304084"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2019.10.005","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Les dysthyro\u00efdies sous immunoth\u00e9rapie anti-canc\u00e9reuse","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2019.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}